Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals

(2012) Andrew Scourfield et al.   AIDS

Antiretroviral neurotoxicity

(2012) Kevin Robertson et al.   JOURNAL OF NEUROVIROLOGY

ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients

(2012) Marelize Swart et al.   Frontiers in Genetics

Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

(2011) Catherine Orrell et al.   ANTIVIRAL THERAPY

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

(2011) E Ngaimisi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis

(2011) Tanuja N. Gengiah et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients

(2011) A. Habtewold et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

(2011) C. Wyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

(2010) Awewura Kwara et al.   AIDS

Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008

(2010) Luigia Elzi   ARCHIVES OF INTERNAL MEDICINE

Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095

(2010) Jeffrey T. Schouten et al.   CLINICAL INFECTIOUS DISEASES

Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

(2010) E Ngaimisi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Nervous System Effects of Antituberculosis Therapy

(2010) Joseph S. Kass et al.   CNS DRUGS

Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation

(2010) E. T. Ogburn et al.   DRUG METABOLISM AND DISPOSITION

Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis

(2010) N. Guo et al.   EUROPEAN RESPIRATORY JOURNAL

Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection

(2010) Y. Jamshidi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV

(2010) B. M. Best et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

(2010) Heather J. Ribaudo et al.   JOURNAL OF INFECTIOUS DISEASES

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

(2010) Laure Elens et al.   PHARMACOGENOMICS

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

(2010) Verena Gounden et al.   AIDS Research and Therapy

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

(2009) Awewura Kwara et al.   AIDS

CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India

(2009) G. Ramachandran et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

(2009) Jackson K. Mukonzo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N2R Study

(2009) Weerawat Manosuthi et al.   CLINICAL INFECTIOUS DISEASES

Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis

(2009) Yuan Ren et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders

(2009) Valerio Tozzi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Outcomes of Nevirapine- and Efavirenz-Based Antiretroviral Therapy When Coadministered With Rifampicin-Based Antitubercular Therapy

(2008) Andrew Boulle   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy

(2008) D. S. Miller et al.   PHARMACOLOGICAL REVIEWS